Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | AGER | Q15109 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635031 | 0.93 | ALPL (0.45) | ALPLALPIALPGKMT2AMEN1 | |
| SCHEMBL4635029 | 0.93 | ALPL (0.45) | ALPLALPIALPGKMT2AMEN1 | |
| SCHEMBL4632972 | 0.80 | SMN1; SMN2 (0.48) | ALPLALPIALPGKMT2AMEN1 | |
| SCHEMBL2187600 | 0.79 | ALPL (0.49) | ALPLALPIALPGKMT2AMEN1 | |
| SCHEMBL2795240 | 0.79 | ALDH1A1 (0.49) | ALPLALPIALPGKMT2AMEN1 | |
| SCHEMBL3949534 | 0.78 | ALDH1A1 (0.51) | ALPLALPIALPGKMT2AMEN1 | |
| SCHEMBL6185781 | 0.77 | RAB9A (0.53) | ALPLALPIALPGKMT2AMEN1 | |
| SCHEMBL27136388 | 0.77 | SMN1; SMN2 (0.51) | ALPLALPIALPGKMT2AMEN1 | |
| SCHEMBL2318136 | 0.77 | ALDH1A1 (0.46) | ALPLALPIALPGKMT2AMEN1 | |
| SCHEMBL10138053 | 0.76 | KDM1A (0.61) | ALPLALPIALPGKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269500-A1 | Process for the Preparation of 4-Aminopyrazole Derivatives | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | claimed |
| EP-1931639-A2 | PROCESS | Astra Zeneca AB (SE) | 2008-06-18 | — | — | EP | claimed |
| WO-2007034183-A2 | PROCESS FOR THE PREPARATION OF 4-AMINOPYRAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | claimed |
| US-20080269500-A1 | Process for the Preparation of 4-Aminopyrazole Derivatives | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269500-A1 | Process for the Preparation of 4-Aminopyrazole Derivatives | CYP3A4, CYP3A43, CYP3A5 | ALPL 2799/4885ALPI 1861/4885ALPG 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.